CRISPR Therapeutics
CRISPR Therapeutics
Explore linked clinical trials.6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-30 | NCT07850076 | |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, autoimmune encephalitis, central nervous system disorder, chronic progressive multiple sclerosis, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease, nervous system disorder, neuromuscular disease, neuromyelitis optica, optic nerve disorder, optic neuritis, spinal cord disorder, stiff-person syndrome | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT07804004 | |
| A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, acquired idiopathic inflammatory myopathy, autoimmune disease, connective tissue disorder, diffuse scleroderma, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nephritis, nervous system disorder, neuromuscular disease, skin disorder, systemic lupus erythematosus, systemic sclerosis, urinary system disorder | Recruiting | Phase 1 | 2026-08-28 | NCT06925542 | |
| A Long-term Follow-up Study in Participants Who Received CTX001 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease, thalassemia | Enrolling by invitation | Phase 3 | 2026-08-11 | NCT04208529 | |
| Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Active, not recruiting | Phase 3 | 2026-07-01 | NCT05356195 | |
| Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Active, not recruiting | Phase 3 | 2026-07-01 | NCT05329649 |